There are 101 resources available
20MO - Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC)
Presenter: Domenica Lorusso
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
Invited Discussant of abstract 20MO
Presenter: Jean Emmanuel Kurtz
Session: Mini Oral session
Resources:
Slides
Webcast
21MO - Limited benefit of molecular profiling in patients with low-grade endometrial cancer
Presenter: Stephanie Vrede
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
27MO - Integrated digital pathology and single-cell analysis identify the spatial and temporal evolution of immune cells networks in epithelial ovarian cancer
Presenter: Eleonora Ghisoni
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
Invited Discussant of abstracts 21MO and 27MO
Presenter: Iain McNeish
Session: Mini Oral session
Resources:
Slides
Webcast
28MO - Real-world whole sequencing data of ovarian cancer patients
Presenter: James Brenton
Session: Mini Oral session
Resources:
Abstract
Slides
Webcast
Invited Discussant of abstract 28MO
Presenter: Liselore Loverix
Session: Mini Oral session
Resources:
Slides
Webcast
Q&A and discussion
Presenter: Jean Emmanuel Kurtz
Session: Mini Oral session
Resources:
Webcast
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase III trial
Presenter: Ning Li
Session: Clinical trial highlights
Resources:
Slides
Webcast
ATHENA (GOG-3020/ENGOT-ov45): A randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Rebecca Kristeleit
Session: Clinical trial highlights
Resources:
Slides
Webcast